New Triple-Drug malaria pill could outsmart resistant parasites

NCT ID NCT05951595

First seen Nov 18, 2025 · Last updated May 14, 2026 · Updated 23 times

Summary

This study tests whether a new triple-combination malaria pill (ALAQ) works as well as current two-drug treatments for uncomplicated malaria. About 1,680 people with malaria will receive either the new triple drug or a standard treatment and be monitored for 42 days. The goal is to see if the triple combo is safe, tolerable, and effective at clearing the parasite without increasing side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ruhuha Health Centre

    RECRUITING

    Ruhuha, Eastern Province, Rwanda

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.